In the ever-evolving field of medical advancements, an experimental cancer treatment known as Targeted Osmotic Lysis (TOL) is emerging as a potential breakthrough for patients battling advanced carcinomas, mesothelioma, melanomas and sarcomas. Developed by Oleander Medical Technologies, TOL therapy has been utilized in veterinary clinics for years and is now being introduced for human patients in Roatan, Honduras. While the treatment has yet to receive FDA approval and clinical trials in the U.S. have not yet commenced, early reports suggest that this novel approach could revolutionize cancer care.
What is TOL Therapy?
TOL therapy leverages the fact that advanced cancers overexpress sodium channels. Using a combination of a pulsed field device and the medication digoxin, the treatment forces cancer cells to take in excess sodium and water, causing them to swell and burst while leaving healthy cells unharmed. TOL therapy represents an extraordinary alternative to traditional cancer treatments like chemotherapy and radiation.
Unlike conventional therapies, TOL therapy does not cause pain, tissue destruction or scarring – just targeted tumor regression.
As awareness of TOL therapy grows, more patients will have access to a non-toxic, non-invasive alternative to chemotherapy and radiation.
The Treatment Process
Patients considering TOL therapy must undergo a thorough screening process to determine eligibility, including a review of medical records and biopsy results. Once approved, they will travel to Roatan, where the treatment is administered in cycles. The standard protocol consists of:
◆ Two days of therapy per week
◆ Three weeks per cycle
◆ Up to three separate cycles, depending on patient response
For full treatment, most patients require one to three trips to Roatan, with follow-up CT and/or PET scans conducted in the U.S. to assess progress. Between treatment cycles, patients should expect periodic scans to monitor tumor regression and overall response to treatment.
How TOL Works
Targeted Osmotic Lysis treatment is a novel combination therapy that utilizes the drug digoxin in conjunction with a low-powered coaxial pulsed electric field-generating device, known as the TOL device.
The device emits pulses at a specific voltage and frequency to repeatedly open sodium ion channels in cancer cell membranes, flooding them with sodium. Meanwhile, digoxin blocks the sodium pumps, preventing the cancer cells from expelling the excess sodium. This imbalance causes an influx of water into the cell through osmosis, leading to cancer cell swelling and rupture. Since advanced cancers overexpress sodium channels and pumps ten-50 times more than normal tissue, TOL selectively targets cancer cells while sparing healthy ones.
The Device & Procedure
The procedure itself is non-invasive and straightforward. Patients take digoxin before lying on an eight-foot-long TOL device – similar in appearance to a CT scanner, but without the confinement, reducing the risk of claustrophobia. The low-power pulsed field is applied to the entire body, and while some patients report feeling warmth in the tumor area, there is no pain. Each session lasts a few hours, and patients can take bathroom breaks as needed. I would describe it as a comfortable process that allows patients to relax while undergoing cutting-edge cancer therapy.
Promising Early Results
While human trials are still in the early stages, anecdotal reports show encouraging outcomes. I had a business associate who was treated for melanoma in Roatan last year, and after just one cycle, he is now cancer-free. To further assist the healing process, the patient later underwent MSC Exosome Therapy (previously discussed in the September 2024 issue of My City).
I am also actively facilitating treatment for another patient with throat cancer and metastatic spread to the lungs – an individual who previously failed radiation and chemotherapy. TOL offers hope to patients who have exhausted conventional treatments.
Accessing TOL Therapy
Since TOL therapy is currently only available in Roatan, patients must travel internationally to receive this pioneering treatment. As awareness of TOL therapy grows, more patients will have access to a non-toxic, non-invasive alternative to chemotherapy and radiation. Those seeking further details on treatment options can reach out to exorejuv@gmail.com.
Financial Considerations
While this groundbreaking treatment offers new hope, financial considerations remain a factor. Regrettably, medical insurance does not cover this treatment, and it can be costly; however, when it comes to your health, there’s nothing more valuable.
With groundbreaking therapies like TOL, the future of cancer treatment may be shifting toward targeted, pain-free approaches that prioritize longevity and quality of life. While further research is necessary, this innovative therapy in Honduras represents a promising frontier in cancer care.
Dr. Jeffrey S. Rohr is a Fenton native and board-certified physician in Anti-Aging and Regenerative Medicine.
Renowned for his expertise in LASIK laser vision correction and cataract surgery, he served the Grand Blanc community and its surroundings for over 20 years before retiring from his ophthalmology practice in 2022.
